WEST LAFAYETTE, Ind., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that a poster will be presented at the European Society for Medical Oncology (ESMO), being held in Madrid, Spain, Sept. 8-12, 2017.
Presentation is as follows:
Abstract #: 793PD
Title: "Phase 1 Study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)"
When: Sunday, Sept. 10, 2017, from 9:15 - 10:30 AM CEST
Session Type: Poster Discussion Session
Title: Genitourinary tumours, prostate
Location: Bilbao Auditorium
About EC1169 and the Phase 1 Trial
EC1169 is an investigational therapeutic SMDC constructed of a high affinity PSMA-targeting ligand conjugated through a bioreleasable linker system to a potent microtubule inhibitor, tubulysin B hydrazide (TubBH). Patient PSMA-status is determined using the investigational companion imaging agent, EC0652. EC1169 and EC0652 are currently being evaluated in a Phase
1b study in up to 50 taxane-exposed mCRPC patients at a maximum clinical EC1169 dose of 6.5 mg/m2. Endocyte has stopped enrollment of taxane-naïve mCRPC patients (ClinicalTrials.gov Identifier: NCT02202447).
The open-label, multicenter, non-randomized study is divided into two parts. The first part, phase 1a, of the study, now complete, was designed to determine the maximum clinical dose and recommended Phase 2 dose of EC1169 in patients with mCRPC.
Endocyte is currently
enrolling the second part, phase 1b, of the study, which is designed to evaluate the safety and efficacy of EC1169 in taxane-exposed patients, with a primary study endpoint of radiographic progression free survival in patients selected as PSMA-positive. The trial is expected to complete enrollment in Q3 2017 with a more mature endpoint assessment by year-end.
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company's SMDCs actively target
receptors that are over-expressed on diseased cells relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In addition, the company continues to pursue applications of the SMDC platform and is working to bring assets toward clinical development in several areas, including EC2629, its dual-targeted DNA crosslinker drug that can attack both TAMs and cancer cells, and its CAR T-Cell SMDC adaptor platform. For additional information, please visit Endocyte's website at www.endocyte.com
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, email@example.com
Source: Endocyte, Inc.
News Provided by Acquire Media